Literature DB >> 7819104

Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera.

G Hess1, P Rose, H Gamm, S Papadileris, C Huber, B Seliger.   

Abstract

Erythropoietin (EPO) is a potent regulator of the viability, proliferation and differentiation of erythroid progenitor cells. Its effect is mediated by binding to the erythropoietin receptor (EPO-R), a member of a new cytokine receptor family. Alterations of the EPO/EPO-R system have recently been shown to be involved in the pathogenesis of familial erythrocytosis and polycythaemia vera (PV). In order to define whether genetic changes in the EPO-R gene and its ligand play a role in the development of PV, the structure and expression levels of the EPO-R and EPO genes were examined in samples from bone marrow and/or peripheral blood mononuclear cells of 24 patients with PV. As expected, EPO serum levels were low and no detectable level of EPO mRNA was found by reverse polymerase chain reaction (RT-PCR) in the peripheral blood mononuclear cells of our PV patients. To search for structural alterations of the EPO-R, cDNA samples were subjected to PCR and SSCP analysis as well as sequencing. Heterogenous expression of EPO-R mRNA was observed without any structural changes, as revealed by RT-SSCP analysis using overlapping primers spanning the whole coding region of the EPO-R gene. Structural integrity of the EPO-R was further confirmed by sequencing of cloned PCR products. These data suggest that the mechanisms for the development of PV do not involve structural changes of the EPO-R gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7819104     DOI: 10.1111/j.1365-2141.1994.tb05119.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.

Authors:  Annedore Respa; Juergen Bukur; Soldano Ferrone; Graham Pawelec; Yingdong Zhao; Ena Wang; Francesco M Marincola; Barbara Seliger
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

4.  Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice.

Authors:  R J D'Andrea; D Harrison-Findik; C M Butcher; J Finnie; P Blumbergs; P Bartley; M McCormack; K Jones; R Rowland; T J Gonda; M A Vadas
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

5.  Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

Authors:  Jacob P Laubach; Ping Fu; Xiaohong Jiang; Kelly H Salter; Anil Potti; Murat O Arcasoy
Journal:  Exp Hematol       Date:  2009-10-06       Impact factor: 3.084

6.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

7.  Prediction of heterogeneous differential genes by detecting outliers to a Gaussian tight cluster.

Authors:  Zihua Yang; Zhengrong Yang
Journal:  BMC Bioinformatics       Date:  2013-03-05       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.